Iopofosine I-131

N/A

Report date: 2026/03/19 20:00:18
NMEFirst In Class

Base Information

Drug NameIopofosine I-131
Drug Alias Name18-(p-[I-131]-iodophenyl)octadecyl phosphocholineIopofosine I 131Iopofosine iodine-131(131)I-CLR1404I-131-CLR1404 +[11] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Nuclides > Iodine > 131I +[4] 
Mechanisms of ActionSerine/threonine-protein kinase AKT1 inhibitorsApoptosis inducers
TargetsSerine/threonine-protein kinase AKT1
Therapy Area/IndicationsSolid tumoursCentral Nervous System LymphomaBrain Neoplasms +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesSpectronRXUniversity Of Wisconsin-MadisonCellectar Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System LymphomaBrain Neoplasms +[17] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A